Evidence map›Paper›PMID 30747392›Full record

ArticleClinical rheumatology2019

Macrophage migration inhibitory factor polymorphisms are a potential susceptibility marker in systemic sclerosis from southern Mexican population: association with MIF mRNA expression and cytokine profile.

Christian Johana Baños-Hernández, José Eduardo Navarro-Zarza, Richard Bucala, Jorge Hernández-Bello, Isela Parra-Rojas, María Guadalupe Ramírez-Dueñas, Samuel García-Arellano, Luis Alexis Hernández-Palma, Andrea Carolina Machado-Sulbarán, José Francisco Muñoz-Valle

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. The Immunogenetics of Systemic Sclerosis.Advances in experimental medicine and biology · 2022
    Article
  7. Association AmongClinical, cosmetic and investigational dermatology · 2022
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Christian Johana Baños-HernándezInstituto de Investigación en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.
José Eduardo Navarro-ZarzaDepartamento de Medicina Interna-Reumatología, Hospital General de Chilpancingo "Dr. Raymundo Abarca Alarcón", Chilpancingo de los Bravo, Guerrero, Mexico.
Richard BucalaDepartment of Medicine/Section of Rheumatology, Yale University School of Medicine, New Haven, CT, USA.
Jorge Hernández-BelloInstituto de Investigación en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.
Isela Parra-RojasDoctorado en Ciencias Biomédicas, Facultad de Ciencias Químico-Biológicas, Universidad Autónoma de Guerrero, Chilpancingo de los Bravo, Guerrero, Mexico.
María Guadalupe Ramírez-DueñasLaboratorio de Inmunología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.
Samuel García-ArellanoInstituto de Investigación en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.
Luis Alexis Hernández-PalmaInstituto de Investigación en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.
Andrea Carolina Machado-SulbaránLaboratorio de Inmunología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.
José Francisco Muñoz-ValleInstituto de Investigación en Ciencias Biomédicas, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico. biologiamolecular@hotmail.com.ORCID http://orcid.org/0000-0002-2272-9260
Universidad de Guadalajara · MXUniversidad Autónoma de Guerrero · MXYale University · US

Funding

EARLY DOXORUBICIN RESISTANT MAMMALIAN LEUKEMIA CELLSF32CA008774 · NCI · TUFTS MEDICAL CENTER · PI SLAPAK, CHRISTOPHER A · 1989 to 1990
–
Consejo Nacional de Ciencia y Tecnolog?a A1-S-8774
6 · The paper itself

Abstract

introductionSystemic sclerosis (SSc) is a complex autoimmune disease, characterized by microvascular lesions, autoimmunity, and fibrosis. It is suggested that MIF participates in the amplification of the proinflammatory process in SSc; moreover, the promoter polymorphisms - 794 CATT MATERIALS AND

methodsA case-control study was carried out that included 50 patients with SSc and 100 control subjects (CS). Both polymorphisms were genotyped by PCR and PCR-RFLP. MIF levels were measured by ELISA kit. The cytokine profile and the MIF mRNA expression were quantified by BioPlex MagPix system and real-time PCR, respectively.

resultsAn association between the - 794 CATT

conclusionThe MIF 7C haplotype is a susceptibility marker for SSc in the southern Mexican population and is associated with MIF mRNA expression. Moreover, there is a positive correlation between MIF serum levels and Th1 and Th17 inflammatory response in SSc.

Indexed as

Polymorphism, Single NucleotideAdultBiomarkersCase-Control StudiesCytokinesFemaleGenetic Predisposition to DiseaseHaplotypesHumansIntramolecular OxidoreductasesMacrophage Migration-Inhibitory FactorsMaleMexicoMiddle AgedPromoter Regions, GeneticRNA, MessengerBiomarkersCytokinesIntramolecular OxidoreductasesMacrophage Migration-Inhibitory FactorsMIF protein, humanRNA, MessengerCytokine profiles Th1/Th2/Th17MIFMIF mRNA expressionPromoter polymorphismsSystemic sclerosis

Identifiers

PMID30747392
OpenAlexW2911828697

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.